Trial Profile
An observational comparative study on Switch to Raltegravir versus continuing on Boosted protease inhibitor (PI) in HIV infected subjects with viral load suppression: French Hospital Database cohort
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2016
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; HIV protease inhibitors
- Indications HIV-1 infections
- Focus Adverse reactions
- 14 Oct 2016 New trial record
- 19 Aug 2016 Results published in the Clinical Infectious Diseases